Creative Medical Technology reports one-year results for AlloStem program

Creative Medical Technology (CELZ) announced one-year follow-up data from the AlloStem Type 2 Diabetes pilot study for late-stage patients. CELZ-201 is an off the shelf, ready-to-use universal and proprietary allogenic cell line developed by the Company. Results demonstrate that CELZ-201 achieved an 80% overall efficacy rate in reducing insulin dependency and stabilizing hemoglobin A1c levels, with no serious adverse effects reported. The study, which included 20 patients-10 receiving CELZ-201 and 10 undergoing optimized medical therapy-validated the safety and efficacy of CELZ-201 through the same infusion procedure used in the Company’s U.S. FDA-cleared Type 1 Diabetes clinical trial, which is currently underway. The absence of safety concerns further supports the potential of CELZ-201 as a breakthrough treatment for late-stage Type 2 Diabetes. Given these results, Creative Medical Technology plans to advance the development of AlloStem for the treatment of late-stage Type 2 Diabetes and explore other potential applications of this therapy to expand the Company’s pipeline.